PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34415720-0 2021 MCP-1-Functionalized, Core-Shell Gold Nanorod@Iron-Based Metal-Organic Framework (MCP-1/GNR@MIL-100(Fe)) for Photothermal Therapy. Iron 46-50 C-C motif chemokine ligand 2 Homo sapiens 0-5 16164630-0 2005 Parenteral iron treatment induces MCP-1 accumulation in plasma, normal kidneys, and in experimental nephropathy. Iron 11-15 C-C motif chemokine ligand 2 Homo sapiens 34-39 16164630-3 2005 Thus, this study tested whether pro-oxidant iron/carbohydrate complexes, used to treat iron deficiency, induce MCP-1 in renal/extrarenal tissues, in plasma, and in the setting of experimental nephropathy. Iron 44-48 C-C motif chemokine ligand 2 Homo sapiens 111-116 16164630-6 2005 Iron effects on liver, lung, spleen, and heart MCP-1 mRNA, and on peritoneal lavage fluid MCP-1 concentrations were assessed. Iron 0-4 C-C motif chemokine ligand 2 Homo sapiens 47-52 16164630-7 2005 Iron pretreatment effects on MCP-1 levels in unilaterally obstructed kidneys vs. contralateral kidneys were determined. Iron 0-4 C-C motif chemokine ligand 2 Homo sapiens 29-34 16164630-18 2005 Finally, iron can increase peritoneal lavage fluid MCP-1 levels. Iron 9-13 C-C motif chemokine ligand 2 Homo sapiens 51-56 34415720-0 2021 MCP-1-Functionalized, Core-Shell Gold Nanorod@Iron-Based Metal-Organic Framework (MCP-1/GNR@MIL-100(Fe)) for Photothermal Therapy. Iron 100-102 C-C motif chemokine ligand 2 Homo sapiens 0-5 34415720-4 2021 In this work, we successfully modified monocyte chemoattractant protein-1 (MCP-1) and iron-based metal-organic framework (MIL-100(Fe)) on the photothermal agent, gold nanorods (GNRs) (i.e., MCP-1/GNR@MIL-100(Fe)), to increase cellular uptake and biocompatibility. Iron 86-90 C-C motif chemokine ligand 2 Homo sapiens 190-195 34415720-4 2021 In this work, we successfully modified monocyte chemoattractant protein-1 (MCP-1) and iron-based metal-organic framework (MIL-100(Fe)) on the photothermal agent, gold nanorods (GNRs) (i.e., MCP-1/GNR@MIL-100(Fe)), to increase cellular uptake and biocompatibility. Iron 130-132 C-C motif chemokine ligand 2 Homo sapiens 39-73 34415720-4 2021 In this work, we successfully modified monocyte chemoattractant protein-1 (MCP-1) and iron-based metal-organic framework (MIL-100(Fe)) on the photothermal agent, gold nanorods (GNRs) (i.e., MCP-1/GNR@MIL-100(Fe)), to increase cellular uptake and biocompatibility. Iron 130-132 C-C motif chemokine ligand 2 Homo sapiens 190-195 34415720-4 2021 In this work, we successfully modified monocyte chemoattractant protein-1 (MCP-1) and iron-based metal-organic framework (MIL-100(Fe)) on the photothermal agent, gold nanorods (GNRs) (i.e., MCP-1/GNR@MIL-100(Fe)), to increase cellular uptake and biocompatibility. Iron 208-210 C-C motif chemokine ligand 2 Homo sapiens 39-73 34415720-4 2021 In this work, we successfully modified monocyte chemoattractant protein-1 (MCP-1) and iron-based metal-organic framework (MIL-100(Fe)) on the photothermal agent, gold nanorods (GNRs) (i.e., MCP-1/GNR@MIL-100(Fe)), to increase cellular uptake and biocompatibility. Iron 208-210 C-C motif chemokine ligand 2 Homo sapiens 75-80 34415720-4 2021 In this work, we successfully modified monocyte chemoattractant protein-1 (MCP-1) and iron-based metal-organic framework (MIL-100(Fe)) on the photothermal agent, gold nanorods (GNRs) (i.e., MCP-1/GNR@MIL-100(Fe)), to increase cellular uptake and biocompatibility. Iron 208-210 C-C motif chemokine ligand 2 Homo sapiens 190-195 17767550-4 2007 The aim of this study was to assess MCP-1 levels in patients with HH and correlate these results with HFE status and iron indexes. Iron 117-121 C-C motif chemokine ligand 2 Homo sapiens 36-41 17767550-11 2007 This study suggests for the first time that a differential expression of MCP-1 protein in patients with HH is associated with the specific HFE genetic component for iron overload. Iron 165-169 C-C motif chemokine ligand 2 Homo sapiens 73-78 14734750-9 2004 Finally, we found that the triptophan catabolite picolinic acid and the iron chelator desferrioxamine, which mimic hypoxia in the induction of gene expression, differentially regulated the expression of MCP-1. Iron 72-76 C-C motif chemokine ligand 2 Homo sapiens 203-208 2355004-4 1990 It was found that the prosthetic heme was modified by a CCl2 moiety derived from BrCCl3 and was covalently bound to histidine residue 93, the normal proximal ligand to the heme-iron. Iron 177-181 C-C motif chemokine ligand 2 Homo sapiens 56-60 34415720-5 2021 The results of TEM, UV-vis, and FTIR all confirmed that we"d synthesized MCP-1/GNR@MIL-100(Fe) successfully, and the MCP-1/GNR@MIL-100(Fe) also showed good biocompatibility. Iron 91-93 C-C motif chemokine ligand 2 Homo sapiens 73-78 34415720-0 2021 MCP-1-Functionalized, Core-Shell Gold Nanorod@Iron-Based Metal-Organic Framework (MCP-1/GNR@MIL-100(Fe)) for Photothermal Therapy. Iron 46-50 C-C motif chemokine ligand 2 Homo sapiens 82-87 34415720-5 2021 The results of TEM, UV-vis, and FTIR all confirmed that we"d synthesized MCP-1/GNR@MIL-100(Fe) successfully, and the MCP-1/GNR@MIL-100(Fe) also showed good biocompatibility. Iron 135-137 C-C motif chemokine ligand 2 Homo sapiens 117-122 31724666-7 2020 Compared to DiDBV2 without iron oxide activation, DiDBV2-Fe indicated strong tumor tropism in response to monocyte chemoattractant protein-1 (CCL2) secreted by U87MG tumor cells. Iron 50-59 C-C motif chemokine ligand 2 Homo sapiens 106-140 33395292-8 2021 Other typical fragment-ions produced from protonated metallocenes included the M(cp)1+ ions (M = Fe or Ni), by elimination of a cyclopentadiene molecule, or the molecular cation, by loss of a H radical. Iron 97-99 C-C motif chemokine ligand 2 Homo sapiens 79-85 31724666-7 2020 Compared to DiDBV2 without iron oxide activation, DiDBV2-Fe indicated strong tumor tropism in response to monocyte chemoattractant protein-1 (CCL2) secreted by U87MG tumor cells. Iron 50-59 C-C motif chemokine ligand 2 Homo sapiens 142-146 30835899-4 2019 Treatment with iron (ferric ammonium citrate, FAC) led to increased expression levels of M1 markers: CCL2, CD14, iNOS, IL-1beta, IL-6, and TNF-alpha; it also increased protein levels of CD68, TNF-alpha, IL-1beta, and IL-6 by flow cytometry. Iron 15-19 C-C motif chemokine ligand 2 Homo sapiens 101-105 20504881-0 2010 Parenteral iron formulations differentially affect MCP-1, HO-1, and NGAL gene expression and renal responses to injury. Iron 11-15 C-C motif chemokine ligand 2 Homo sapiens 51-56 30010336-2 2018 The unusually large quadrupole splitting (Delta EQ = +2.2 mm s-1) and asymmetric parameter (eta = 0.9) of the five-coordinate heme carbene [Fe(TTP)(CCl2)], which is the largest among all known low spin ferrohemes, has driven investigations by means of Mossbauer effect Nuclear Resonance Vibrational Spectroscopy (NRVS). Iron 140-142 C-C motif chemokine ligand 2 Homo sapiens 148-152 21183736-0 2011 Serum hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in patients with metabolic syndrome alterations. Iron 30-34 C-C motif chemokine ligand 2 Homo sapiens 50-55 21183736-3 2011 METHODS AND RESULTS: Manipulation of iron status with ferric ammonium citrate and hepcidin-25 induced monocyte chemoattractant protein (MCP)-1 and interleukin-6 in human differentiating monocytes of patients with hyperferritinemia associated with the metabolic syndrome (n=11), but not in subjects with hemochromatosis or HFE mutations impairing iron accumulation (n=15), and the degree of induction correlated with the presence of carotid plaques, detected by echocolor-Doppler. Iron 37-41 C-C motif chemokine ligand 2 Homo sapiens 102-142 21183736-4 2011 In monocytes of healthy subjects (n=7), iron and hepcidin increased the mRNA levels and release of MCP-1, but not of interleukin-6. Iron 40-44 C-C motif chemokine ligand 2 Homo sapiens 99-104 21183736-6 2011 CONCLUSIONS: Hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in high-risk individuals with metabolic alterations. Iron 37-41 C-C motif chemokine ligand 2 Homo sapiens 57-62 19228389-0 2009 Influence of HFE variants and cellular iron on monocyte chemoattractant protein-1. Iron 39-43 C-C motif chemokine ligand 2 Homo sapiens 47-81 19228389-6 2009 The influence of cellular iron secretion on the potent chemokine monocyte chemoattractant protein-1 (MCP-1) was assessed using ferric ammonium citrate and the iron chelator, desferroxamine. Iron 26-30 C-C motif chemokine ligand 2 Homo sapiens 65-99 19228389-6 2009 The influence of cellular iron secretion on the potent chemokine monocyte chemoattractant protein-1 (MCP-1) was assessed using ferric ammonium citrate and the iron chelator, desferroxamine. Iron 26-30 C-C motif chemokine ligand 2 Homo sapiens 101-106 19228389-6 2009 The influence of cellular iron secretion on the potent chemokine monocyte chemoattractant protein-1 (MCP-1) was assessed using ferric ammonium citrate and the iron chelator, desferroxamine. Iron 159-163 C-C motif chemokine ligand 2 Homo sapiens 65-99 19228389-6 2009 The influence of cellular iron secretion on the potent chemokine monocyte chemoattractant protein-1 (MCP-1) was assessed using ferric ammonium citrate and the iron chelator, desferroxamine. Iron 159-163 C-C motif chemokine ligand 2 Homo sapiens 101-106 19228389-10 2009 We further examined the relationship between iron and MCP-1 and found MCP-1 secretion tightly associated with intracellular iron status. Iron 45-49 C-C motif chemokine ligand 2 Homo sapiens 54-59 19228389-10 2009 We further examined the relationship between iron and MCP-1 and found MCP-1 secretion tightly associated with intracellular iron status. Iron 45-49 C-C motif chemokine ligand 2 Homo sapiens 70-75 19228389-10 2009 We further examined the relationship between iron and MCP-1 and found MCP-1 secretion tightly associated with intracellular iron status. Iron 124-128 C-C motif chemokine ligand 2 Homo sapiens 70-75